Jefferies Group started coverage on shares of Anthera Pharmaceuticals (NASDAQ: ANTH) in a research note issued on Tuesday. The firm set a “buy” rating and a $2.00 price target on the stock.
Shares of Anthera Pharmaceuticals opened at 0.571 on Tuesday. Anthera Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $6.54. The stock’s 50-day moving average is currently $0.6. The company’s market cap is $45.2 million.
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
